Show simple item record

dc.contributor.authorBarrero Hernández, Francisco Javier 
dc.contributor.authorMallada-Frechin, J
dc.contributor.authorMartínez-Ginés, ML
dc.contributor.authorMarzo, ME
dc.contributor.authorMeca-Lallana, V
dc.contributor.authorIzquierdo, G
dc.contributor.authorAra, JR
dc.contributor.authorOreja-Guevara, C
dc.contributor.authorMeca-Lallana, J
dc.contributor.authorForero, L
dc.contributor.authorSánchez-Vera, I
dc.contributor.authorMoreno, MJ
dc.date.accessioned2024-09-04T07:57:19Z
dc.date.available2024-09-04T07:57:19Z
dc.date.issued2020-04
dc.identifier.citationBarrero F, Mallada-Frechin J, Martínez-Ginés ML, Marzo ME, Meca-Lallana V, Izquierdo G, Ara JR, Oreja-Guevara C, Meca-Lallana J, Forero L, Sánchez-Vera I, Moreno MJ; in representation of the MS NEXT study investigators. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. PLoS One. 2020 Apr 2;15(4):e0230846. doi: 10.1371/journal.pone.0230846. PMID: 32240213; PMCID: PMC7117743.es_ES
dc.identifier.urihttps://hdl.handle.net/10481/93891
dc.language.isoenges_ES
dc.publisherPLOSes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleSpanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT studyes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1371/journal.pone.0230846.
dc.type.hasVersionAMes_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional